SCHEMBL17500296

SCHEMBL17500296

CN1C(=O)C2Cc3c(n(Cc4ccc(C(=O)NO)cc4)c4ccccc34)CN2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 19/20 1.00
▸ HDAC2 Q92769 8/20 0.74
▸ HDAC8 Q9BY41 8/20 0.74
▸ HDAC1 Q13547 4/20 0.74
▸ HDAC10 Q969S8 4/20 0.74
▸ HDAC4 P56524 3/20 0.74
▸ HDAC3 O15379 3/20 0.64
▸ NCOR2 Q9Y618 3/20 0.64
▸ HDAC7 Q8WUI4 2/20 0.64
▸ HDAC11 Q96DB2 2/20 0.64
▸ HDAC5 Q9UQL6 2/20 0.64
▸ HDAC9 Q9UKV0 1/20 0.59
▸ ENPP2 Q13822 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17520599 1.00 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL19138959 0.90 HDAC6 (0.81) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL19168584 0.90 HDAC6 (0.81) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL17520628 0.90 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL17520423 0.89 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL19167870 0.88 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL19138935 0.88 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL17520522 0.88 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL19138923 0.88 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL19161934 0.86 HDAC6 (0.75) HDAC6HDAC2HDAC8HDAC1HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177621-B1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIV REGENSBURG (DE) 2021-11-10 — — EP disclosed
US-10106540-B2 HDAC6 inhibitors and their uses UNIVERSITÄT REGENSBURG (DE) 2018-10-23 — — US disclosed
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES Universitätsklinikum Jena (DE) 2017-07-27 — — US disclosed
EP-3177621-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES Universität Regensburg (DE) 2017-06-14 — — EP disclosed
WO-2016020369-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2016-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES HDAC6, HDAC5, HDAC4 HDAC6 1/4885HDAC2 6/4885HDAC8 10/4885
US-10106540-B2 HDAC6 inhibitors and their uses HDAC6, HDAC5, HDAC4 HDAC6 1/4885HDAC2 6/4885HDAC8 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback